Legal Representation
Attorney
Don D. Cha
USPTO Deadlines
Application History
41 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 14, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 14, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 7, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 7, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 7, 2025 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 7, 2025 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| May 30, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| May 30, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Mar 7, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Mar 7, 2025 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Jan 7, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Nov 26, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Nov 26, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 20, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 29, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Oct 29, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 29, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Oct 29, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Oct 29, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Oct 24, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 24, 2024 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Oct 24, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 17, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 17, 2024 | PETG | O | PETITION TO REVIVE-GRANTED | Loading... |
| Jul 17, 2024 | NREV | E | NOTICE OF REVIVAL - E-MAILED | Loading... |
| Jul 17, 2024 | PROA | I | TEAS PETITION TO REVIVE RECEIVED | Loading... |
| Apr 11, 2024 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Apr 11, 2024 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Jan 11, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jan 11, 2024 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Jan 11, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 2, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 1, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 1, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Sep 1, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Sep 1, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Sep 1, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 30, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 10, 2022 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Dec 9, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 22, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the prevention of cancer or tumor; Pharmaceutical preparations for the treatment and prevention of cancer or tumor; Pharmaceutical preparations for the treatment of cancer or tumor; Pharmaceutical preparations for cancer or tumor; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer or tumor; House mark for pharmaceutical research and development
First Use Anywhere:
Feb 1, 2025
First Use in Commerce:
Feb 1, 2025
Class 042
Pharmaceutical products development; Pharmaceutical research and development; Development of pharmaceutical preparations and medicines; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research on the subject of pharmaceuticals; Testing of pharmaceuticals
First Use Anywhere:
Jan 1, 2023
First Use in Commerce:
Jan 1, 2023
Additional Information
Design Mark
The mark consists of a stylized blue "M" to the left of a stylized light blue "B" above the stylized blue wording "MAINLINE BIOSCIENCE" above stylized blue Asian characters
Color Claim
The color(s) blue and light blue is/are claimed as a feature of the mark.
Other
The mark was first used anywhere in a different form other than that sought to be registered at least as early as 01/01/2018
Other
The mark was first used in commerce in a different form other than that sought to be registered at least as early as 01/01/2018
Other
The mark was first used anywhere in a different form other than that sought to be registered at least as early as 01/01/2018
Other
The mark was first used in commerce in a different form other than that sought to be registered at least as early as 01/01/2018
Other
The non-Latin characters in the mark transliterate to "ZHULIU YUAN SHENGWUKEJI" and this means "MAIN SOURCE BIOTECHNOLOGY" in English.
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOSCIENCES"